Leerink Swann


Leerink Swann Boosts Price Target on Ionis Pharmaceuticals Inc (IONS); Here’s Why

Following the news that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has secured FDA approval in a major way for its pipeline drug Spinraza in the indication …

Analysts Weigh in on Two Falling Healthcare Stocks: McKesson Corporation (MCK) and Cempra Inc (CEMP)

McKesson Corporation McKesson Corporation (NYSE:MCK) shares are falling nearly 22% today after the company reported disappointing results for the fiscal second-quarter and issued lackluster guidance. MCK posted …

Leerink Swann Remains Positive on Bristol-Myers Squibb Co (BMY) Despite Disappointing Checkmate-026 Data Release at ESMO

In a research report released yesterday, Leerink Swann analyst Seamus Fernandez reiterated an Outperform rating on shares of Bristol-Myers Squibb Co (NYSE:BMY), after the …

This Top Analyst Initiates Outperform on Ariad Pharmaceuticals, Inc. (ARIA); Sees 45% Upside For The Stock

In a research report released on Monday, Leerink top analyst Michael Schmidt initiated coverage on shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) with a price …

Leerink Swann Analyst Reiterates Outperform Rating on bluebird bio Inc (BLUE)

Leerink Swann analyst, Michael Schmidt, reiterates his Outperform rating on bluebird bio Inc (NASDAQ:BLUE) after the company reported its 2Q16 financial results. The analyst couples his …

Leerink Swann Analyst Reiterates Outperform Rating on Edwards LifeSciences Corp (EW)

Leerink Swann analyst Danielle Antalffy reiterates an Outperform rating on Edwards Lifesciences Corp (NYSE:EW) following the company’s better than-expected sales report, marking the company’s 9th …

Leerink Weighs In on Juno Therapeutics Inc (JUNO) Following Acquisition of RedoxTherapies

Analyst Michael Schmidt from Leerink Swann shared his thoughts on Juno Therapeutics Inc (NASDAQ:JUNO), following its $10 million acquisition of RedoxTherapies. In addition to …

Leerink Swann Slashes Price Target for Ionis Pharmaceuticals Inc (IONS); Here’s Why

On Wednesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) hosted an R&D day in NYC, where it framed the antisense/IONS vs RNAi debate particularly as it pertains to …

Leerink Pounds the Table On Exelixis, Inc. (EXEL)

Leerink Swann analyst Michael Schmidt was out pounding the table on Exelixis, Inc. (NASDAQ:EXEL) Tuesday, reiterating an Outperform rating and price target of $10, which represents a potential upside …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts